- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Inflammation
Session Date/Time: Tuesday 08/10/2013 | 16:30-18:00
Paper Time: 16:42
Venue: Auditorium (First Floor)
First Author: : A.Deka INDIA
Co Author(s): : S. Saikia
To evaluate the safety profile of intracameral moxifloxacin 0.5% ophthalmic solution in terms of anterior chamber (AC) reaction and endothelial toxicity.
This prospective study was conducted from June 2009 to July 2012. The patients were divided into two groups. Group 1, 287 cases were operated between January 2009 to December 2011, received 0.1 ml of intracameral moxifloxacin (Vigamox, Alcon Lab.) 0.5 % ophthalmic solution at the end of the surgery. Group 2, included 189 cases, were operated between January 2012 to July 2012, where 0.1 ml of generic moxifloxacin (Moxigram, Microvision lab) 0.5 % ophthalmic solution was injected intracamerally at the end of the surgery. All patients were examined for AC reaction, corneal thickness and retinal toxicity.
There was no statistically significant difference in corneal oedema between the two groups. Anterior chamber reaction and retinal toxicity on the 1st postoperative day was not different in both groups. In group 1, 2.5% cases had endophthalmitis compared to 0.5% in group 2.
Generic Intracameral moxifloxacin 0.5% ophthalmic solution seems to be as safe as research molecule and can be used safely as prophylaxis against endophthalmitis.
Please wait while information is loading.